{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:05:28Z","timestamp":1775732728431,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Lori and Randy Benderson"},{"name":"Elaine and Eduardo Saverin Foundation"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019794","name":"MacroGenics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"name":"National Cancer Institute (NCI) Breast Cancer SPORE","award":["P50CA168504 to DF\/HCC"],"award-info":[{"award-number":["P50CA168504 to DF\/HCC"]}]},{"DOI":"10.13039\/100011495","name":"Massachusetts Life Sciences Center","doi-asserted-by":"publisher","award":["Dana-Farber Cancer Institute project number 6395601"],"award-info":[{"award-number":["Dana-Farber Cancer Institute project number 6395601"]}],"id":[{"id":"10.13039\/100011495","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-026-00922-3","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:05:46Z","timestamp":1772204746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)"],"prefix":"10.1038","volume":"12","author":[{"given":"Sarah L.","family":"Sammons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"DiLullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xochitl C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasnim","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romualdo","family":"Barroso-Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther Ritah","family":"Ogayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne G.","family":"Waks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana","family":"Schlam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Ligibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C.","family":"Garrido-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"922_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"922_CR2","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","volume":"21","author":"S Dawood","year":"2010","unstructured":"Dawood, S., Broglio, K., Ensor, J., Hortobagyi, G. N. & Giordano, S. H. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann. Oncol. 21, 2169\u20132174 (2010).","journal-title":"Ann. Oncol."},{"key":"922_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432442","volume":"44","author":"C Corti","year":"2024","unstructured":"Corti, C. et al. Systemic therapy in breast cancer. Am. Soc. Clin. Oncol. Educ. Book 44, e432442 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"922_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4076-4","volume":"18","author":"A Lafourcade","year":"2018","unstructured":"Lafourcade, A. et al. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. BMC Cancer 18, 171 (2018).","journal-title":"BMC Cancer"},{"key":"922_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ijc.31914","volume":"144","author":"MC van Maaren","year":"2019","unstructured":"van Maaren, M. C. et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J. Cancer 144, 263\u2013272 (2019).","journal-title":"Int J. Cancer"},{"key":"922_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-021-06233-4","volume":"189","author":"JP Leone","year":"2021","unstructured":"Leone, J. P. et al. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 189, 203\u2013212 (2021).","journal-title":"Breast Cancer Res Treat."},{"key":"922_CR7","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836\u20131846 (2017).","journal-title":"N. Engl. J. Med"},{"key":"922_CR8","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1111\/j.1753-4887.2012.00493.x","volume":"70","author":"LK Ursell","year":"2012","unstructured":"Ursell, L. K., Metcalf, J. L., Parfrey, L. W. & Knight, R. Defining the human microbiome. Nutr. Rev. 70, S38\u2013S44 (2012).","journal-title":"Nutr. Rev."},{"key":"922_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","volume":"30","author":"D Zheng","year":"2020","unstructured":"Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492\u2013506 (2020).","journal-title":"Cell Res."},{"key":"922_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","volume":"157","author":"Y Belkaid","year":"2014","unstructured":"Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121\u2013141 (2014).","journal-title":"Cell"},{"key":"922_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/MOG.0000000000000139","volume":"31","author":"AB Shreiner","year":"2015","unstructured":"Shreiner, A. B., Kao, J. Y. & Young, V. B. The gut microbiome in health and in disease. Curr. Opin. Gastroenterol. 31, 69\u201375 (2015).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"922_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1084\/jem.20180448","volume":"216","author":"J Durack","year":"2019","unstructured":"Durack, J. & Lynch, S. V. The gut microbiome: relationships with disease and opportunities for therapy. J. Exp. Med. 216, 20\u201340 (2019).","journal-title":"J. Exp. Med."},{"key":"922_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.chom.2011.10.003","volume":"10","author":"CS Plottel","year":"2011","unstructured":"Plottel, C. S. & Blaser, M. J. Microbiome and malignancy. Cell Host Microbe 10, 324\u2013335 (2011).","journal-title":"Cell Host Microbe"},{"key":"922_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"922_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"922_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"922_CR17","doi-asserted-by":"publisher","unstructured":"Kwa, M., Plottel, C. S., Blaser, M. J. & Adams, S. The intestinal microbiome and estrogen receptor-positive female breast cancer. J. Natl. Cancer Inst. 108, https:\/\/doi.org\/10.1093\/jnci\/djw029 (2016).","DOI":"10.1093\/jnci\/djw029"},{"key":"922_CR18","doi-asserted-by":"publisher","first-page":"P3-09-16","DOI":"10.1158\/1538-7445.SABCS19-P3-09-16","volume":"80","author":"RB de Sousa","year":"2020","unstructured":"de Sousa, R. B. et al. Abstract P3-09-16: fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) +\/- pembrolizumab (P) for hormone receptor positive (HR+) metastatic breast cancer (MBC). Cancer Res. 80, P3-09-16\u2013P03-09-16 (2020).","journal-title":"Cancer Res."},{"key":"922_CR19","doi-asserted-by":"publisher","first-page":"PD11-05","DOI":"10.1158\/1538-7445.SABCS22-PD11-05","volume":"83","author":"R Barroso-Sousa","year":"2023","unstructured":"Barroso-Sousa, R. et al. Abstract PD11-05: PD11-05 Gut microbiome signatures correlate with overall survival among patients receiving eribulin with or without pembrolizumab for hormone receptor-positive metastatic breast cancer. Cancer Res. 83, PD11-05\u2013PD11-05 (2023).","journal-title":"Cancer Res."},{"key":"922_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/jncimonographs\/lgq035","volume":"2010","author":"DC Allred","year":"2010","unstructured":"Allred, D. C. Ductal carcinoma in situ: terminology, classification, and natural history. J. Natl. Cancer Inst. Monogr. 2010, 134\u2013138 (2010).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"922_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","volume":"121","author":"M van Seijen","year":"2019","unstructured":"van Seijen, M. et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br. J. Cancer 121, 285\u2013292 (2019).","journal-title":"Br. J. Cancer"},{"key":"922_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/11769343211057573","volume":"17","author":"P Yang","year":"2021","unstructured":"Yang, P., Wang, Z., Peng, Q., Lian, W. & Chen, D. Comparison of the gut microbiota in patients with benign and malignant breast tumors: a pilot study. Evolut. Bioinform. 17, 11769343211057573 (2021).","journal-title":"Evolut. Bioinform."},{"key":"922_CR23","doi-asserted-by":"publisher","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","volume":"14","author":"R Sender","year":"2016","unstructured":"Sender, R., Fuchs, S. & Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016).","journal-title":"PLoS Biol."},{"key":"922_CR24","first-page":"17","volume":"13","author":"MJ Bull","year":"2014","unstructured":"Bull, M. J. & Plummer, N. T. Part 1: the human gut microbiome in health and disease. Integr. Med. 13, 17\u201322 (2014).","journal-title":"Integr. Med."},{"key":"922_CR25","doi-asserted-by":"publisher","unstructured":"Goedert, J. J. et al. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J. Natl. Cancer Inst. 107, https:\/\/doi.org\/10.1093\/jnci\/djv147 (2015).","DOI":"10.1093\/jnci\/djv147"},{"key":"922_CR26","doi-asserted-by":"publisher","unstructured":"Mik\u00f3, E. et al. Microbiome-microbial metabolome-cancer cell interactions in breast cancer-familiar, but unexplored. Cells 8, https:\/\/doi.org\/10.3390\/cells8040293 (2019).","DOI":"10.3390\/cells8040293"},{"key":"922_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0515-3","volume":"6","author":"J Zhu","year":"2018","unstructured":"Zhu, J. et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome. Microbiome 6, 136 (2018).","journal-title":"Microbiome"},{"key":"922_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32770","volume":"10","author":"N Li","year":"2024","unstructured":"Li, N. et al. Impact of the gut microbiome on response and toxicity to chemotherapy in advanced esophageal cancer. Heliyon 10, e32770 (2024).","journal-title":"Heliyon"},{"key":"922_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-020-00811-2","volume":"8","author":"Y Heshiki","year":"2020","unstructured":"Heshiki, Y. et al. Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome 8, 28 (2020).","journal-title":"Microbiome"},{"key":"922_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0672-4","volume":"11","author":"BA Peters","year":"2019","unstructured":"Peters, B. A. et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019).","journal-title":"Genome Med."},{"key":"922_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ccell.2022.11.013","volume":"41","author":"H Teng","year":"2023","unstructured":"Teng, H. et al. Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer. Cancer Cell 41, 124\u2013138.e126 (2023).","journal-title":"Cancer Cell"},{"key":"922_CR32","doi-asserted-by":"publisher","first-page":"e703","DOI":"10.1093\/oncolo\/oyad060","volume":"28","author":"G Vernaci","year":"2023","unstructured":"Vernaci, G. et al. Characterization of gut microbiome composition in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy. Oncologist 28, e703\u2013e711 (2023).","journal-title":"Oncologist"},{"key":"922_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14177-z","volume":"11","author":"A Vich Vila","year":"2020","unstructured":"Vich Vila, A. et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun. 11, 362 (2020).","journal-title":"Nat. Commun."},{"key":"922_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/nu7010017","volume":"7","author":"MA Conlon","year":"2014","unstructured":"Conlon, M. A. & Bird, A. R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients 7, 17\u201344 (2014).","journal-title":"Nutrients"},{"key":"922_CR35","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1136\/gutjnl-2019-320204","volume":"69","author":"RK Weersma","year":"2020","unstructured":"Weersma, R. K., Zhernakova, A. & Fu, J. Interaction between drugs and the gut microbiome. Gut 69, 1510\u20131519 (2020).","journal-title":"Gut"},{"key":"922_CR36","doi-asserted-by":"publisher","unstructured":"Waks, A. G. et al. Abstract LB1-02: MARGOT\/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel\/margetuximab\/pertuzumab (TMP) vs paclitaxel\/trastuzumab\/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer. Clin. Cancer Res. 31, LB1\u201302 (2025). https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-LB1-02.","DOI":"10.1158\/1557-3265.SABCS24-LB1-02"},{"key":"922_CR37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2019.01.001","volume":"176","author":"E Pasolli","year":"2019","unstructured":"Pasolli, E. et al. Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle. Cell 176, 649\u2013662.e620 (2019).","journal-title":"Cell"},{"key":"922_CR38","doi-asserted-by":"publisher","first-page":"e1009442","DOI":"10.1371\/journal.pcbi.1009442","volume":"17","author":"H Mallick","year":"2021","unstructured":"Mallick, H. et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput. Biol. 17, e1009442 (2021).","journal-title":"PLoS Comput. Biol."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00922-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00922-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00922-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:19:27Z","timestamp":1775729967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00922-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00922-3","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S. reports serving as a consultant for and\/or on the advisory boards of AstraZeneca, Daiichi Sankyo, Gilead Sciences, Lilly, Novartis, Pfizer, Incyclix, Sermonix, and Seagen; and research funding from Alterome, Daiichi Sankyo, Iambic, Stemline\/Menarini, Pfizer, Seagen, Sermonix, and Relay Therapeutics. N.U.L. declares institutional research support from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, and AstraZeneca; consulting honoraria from Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Olema Pharmaceuticals, Stemline\/Menarini, Artera Inc., Eisai, Shorla Oncology, Pfizer, and Denali Therapeutics; royalties from UptoDate (book); and travel support from Olema, AstraZeneca, and DSI. A.G.W. declares research funding to the institution from Gilead, Genentech, Macrogenics, and Merck; serving on the steering committee of AMBRX; and serving as a consultant and paid speaker for AstraZeneca. A.G.-C. declares research funding to institution from Gilead Sciences, AstraZeneca, Daiichi- Sankyo, Merck, Zenith Epigenetics, Bristol-Myers Squibb, Novartis, Biovica, Foundation Medicine, 4D Path, Precede Biosciences, and Bicycle Therapeutics; scientific advisory board service\/consulting for AstraZeneca, Daiichi-Sankyo, Novartis, Pfizer, and Gilead Sciences; serving as a speaker for\/honoraria from AstraZeneca, Daiichi-Sankyo, Gilead Sciences, and Roche\/Genentech; and travel\/other support from Roche\/Genentech, Gilead Sciences, AstraZeneca, Daiichi Sankyo, Novartis, and Merck. E.A.M. reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche\/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche\/Genentech (via SU2C grant) and Gilead. E.A.M. also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. S.M.T. reports consulting or advisory roles for Novartis, Pfizer\/Seagen, Merck, Eli Lilly, AstraZeneca, Genentech\/Roche, Eisai, Bristol Myers Squibb\/Systimmune, Daiichi Sankyo, Gilead, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Artios Pharma, Menarini\/Stemline, Aadi Bio, Bayer, Jazz Pharmaceuticals, Natera, Tango Therapeutics, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Launch Therapeutics, Zuellig Pharma, Johnson&Johnson\/Ambrx, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, Summit Therapeutics, Avenzo Therapeutics, Aktis Oncology, Celcuity, Boehringer Ingelheim, Samsung Bioepis, Olema Pharmaceuticals, Tempus, Boundless Bio, and Denali Therapeutics; research funding from Genentech\/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, AstraZeneca, NanoString Technologies, Gilead, Seagen, OncoPep, Daiichi Sankyo, Menarini\/Stemline, Jazz Pharmaceuticals, and Olema Pharmaceuticals; and travel support from Lilly, Gilead, Jazz Pharmaceuticals, Pfizer, Arvinas, and Roche. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}